gynäkologie und geburtshilfe
Intrauterinpessare (IUDs: IUD)
Literatur
1.Nelson A, Apter D, Hauck B, et al: Two low-doselevonorgestrelintrauterine contraceptive systems: a randomized controlled trial [published correction appears inObstet Gynecol123(5):1109, 2014].Obstet Gynecol122(6):1205-1213, 2013. doi:10.1097/AOG.0000000000000019 2.Jensen JT, Lukkari-Lax E, Schulze A, et al: Contraceptive efficacy and safety of the 52-mglevonorgestrelintrauterine system for up to 8 years: findings from the Mirena Extension Trial.Am J Obstet Gynecol227(6):873.e1-873.e12, 2022. doi:10.1016/j.ajog.2022.09.007 3.Creinin MD, Schreiber CA, Turok DK, et al:Levonorgestrel52 mg intrauterine system efficacy and safety through 8 years of use.Am J Obstet Gynecol227(6):871.e1-871.e7, 2022. doi:10.1016/j.ajog.2022.05.022 4.Long-term reversible contraception. Twelve years of experience with the TCu380A and TCu220C.Contraception56(6):341-352, 1997. 5.Grentzer JM, Peipert JF, Zhao Q, et al: Risk-based screening forChlamydia trachomatisandNeisseria gonorrhoeaeprior to intrauterine device insertion.Contraception92(4):313-318, 2015. doi:10.1016/j.contraception.2015.06.012 6.Mody SK, Farala JP, Jimenez B, et al: Paracervical block for intrauterine device placement among nulliparous women: A randomized controlled trial,Obstet Gynecol132 (3): 575–582, 2018. doi: 10.1097/AOG.0000000000002790 7.Curtis KM, Jatlaoui TC, Tepper NK, et al: U.S. Selected Practice Recommendations for Contraceptive Use, 2016.MMWR Recomm Rep65 (4):1–66, 2016. doi: 10.15585/mmwr.rr6504a1 8.Jareid M, Thalabard JC, Aarflot M, et al:Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer: Results from the NOWAC Study.Gynecol Oncol149 (1), 127–132, 2018, doi.org/10.1016/j.ygyno.2018.02.006 9.Prabhakaran S, Chuang A: In-office retrieval of intrauterine contraceptive devices with missing strings.Contraception83(2):102-106, 2011. doi:10.1016/j.contraception.2010.07.004 